Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 20%[21] - The company reported a total revenue of CNY 299.30 million, a decrease of 52.84% compared to the same period last year[28] - Net profit attributable to shareholders was CNY 192.20 million, down 56.58% year-on-year, while the net profit after deducting non-recurring gains and losses was CNY 152.78 million, a decline of 63.75%[28] - Cash flow from operating activities was CNY 115.36 million, representing a decrease of 70.43% compared to the previous year[28] - The company achieved revenue of CNY 1.08 billion from COVID-19 related business, accounting for 36.20% of total revenue, but this was a 76.33% decline year-on-year[40] - Non-COVID-19 related business revenue was CNY 1.91 billion, showing a year-on-year growth of 7.88%[40] - The company's operating revenue for the reporting period was ¥299,303,254.39, a decrease of 52.84% compared to ¥634,698,110.16 in the same period last year, primarily due to a decline in revenue from COVID-19 related products[76] - The company's cash flow from operating activities decreased by 70.43% to ¥115,360,989.28, primarily due to reduced revenue from COVID-19 related business[76] Profitability and Margins - The gross profit margin improved to 60%, up from 55% in the same period last year[21] - The gross profit margin for recombinant proteins was 89.93%, while for antibodies it was 96.13%, indicating strong profitability in these segments despite a significant drop in revenue[80] Research and Development - The company has allocated RMB 100 million for research and development in 2022, a 30% increase compared to the previous year[21] - The company has invested heavily in R&D, maintaining a leading position in the domestic biological reagent industry, and has developed multiple core technology platforms to meet market demands efficiently[63] - The company’s R&D investment increased by 28.32% to ¥23,457,860.61 from ¥18,280,828.79 in the previous year, reflecting a commitment to enhancing its core competitiveness[76] - The company has a high-quality team with 37 PhDs, and nearly one-third of employees hold graduate degrees, enhancing its R&D capabilities[71] Market Expansion and Strategy - The company plans to launch three new products in Q4 2022, focusing on advanced biotechnologies[21] - The company is expanding its market presence in Europe, with a new office opening in Germany by the end of 2022[21] - A strategic acquisition of a biotech firm is in progress, aimed at enhancing R&D capabilities and product offerings[21] - The company has established local teams in both domestic and international markets, with subsidiaries in Taizhou and Suzhou expected to commence operations within the year, supporting rapid growth in cell culture and CRO services[44] - The overseas subsidiaries in Japan have begun operations, while the US and European subsidiaries are enhancing their business teams and expanding market activities to improve customer relationship management and brand influence[44] - The company has expanded its market presence internationally, establishing sales teams in developed countries such as the US, Germany, and Japan, with products sold in over 90 countries[72] Product Development and Quality Control - The company successfully established a production technology platform for full-length multi-pass membrane proteins, filling a gap in its product offerings[43] - The company introduced high-quality GMP-grade cytokine products, enhancing product purity and activity to meet industrial cell therapy demands[43] - The company has developed a comprehensive quality control system to ensure product quality and stability, contributing to a good reputation and expanding its customer base[65] - The company has established a comprehensive quality management system, achieving certifications such as ISO9001 and ISO13485, to ensure product quality throughout its lifecycle[55] Risks and Challenges - The company has identified potential risks related to supply chain disruptions and is implementing measures to mitigate these risks[4] - The company faces risks of revenue decline due to the potential decrease in demand for COVID-19 related products as the pandemic situation stabilizes[105] - The company is at risk of core technology leakage, which could adversely affect its operations and market competitiveness[107] - The competitive landscape in the life sciences and biopharmaceutical sectors is intensifying, necessitating continuous improvement in technology and product quality[110] - Trade tensions, particularly with the U.S., pose a risk to the company's market position and pricing competitiveness[111] Shareholder and Governance - The company held its annual general meeting on March 21, 2022, with an investor participation rate of 75.17%[120] - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[122] - There were no changes in the company's board of directors, supervisors, or senior management during the reporting period[121] - The company did not have any significant environmental issues or administrative penalties during the reporting period[127] - The company actively engages in social responsibility initiatives and maintains good communication with stakeholders[135] - The company adheres to relevant laws and regulations to protect the rights of shareholders and employees[130] Financial Position - Cash and cash equivalents at the end of the reporting period amounted to ¥2,842,693,663.49, representing 44.38% of total assets, an increase of 2.69% compared to the previous year[81] - Trading financial assets decreased to ¥3,105,935,138.35, accounting for 48.49% of total assets, a decline of 4.31% from the previous year[81] - Accounts receivable stood at ¥146,727,810.29, which is 2.29% of total assets, showing a slight increase of 0.06% compared to the previous year[81] - Inventory increased to ¥34,917,186.15, representing 0.55% of total assets, up by 0.19% from the previous year[81] - Fixed assets rose to ¥85,021,646.22, accounting for 1.33% of total assets, an increase of 0.47% year-on-year[81] - As of June 30, 2022, the company's total current assets amounted to approximately CNY 6.16 billion, a decrease of about 8.26% from CNY 6.72 billion at the beginning of the year[198] - The company's cash and cash equivalents were CNY 2.84 billion, down from CNY 2.87 billion at the start of the year, indicating a decline of approximately 1.47%[198] - The trading financial assets decreased to CNY 3.10 billion from CNY 3.64 billion, reflecting a reduction of about 14.66%[198] - Accounts receivable stood at CNY 146.73 million, a slight decrease from CNY 153.45 million, representing a decline of approximately 4.4%[198] - Inventory increased significantly to CNY 34.92 million from CNY 24.75 million, marking an increase of about 41.1%[198]

北京义翘神州科技股份有限公司 2022 年第一季度报告全文 证券代码：301047 证券简称：义翘神州 公告编号：2022-037 北京义翘神州科技股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的 真实、准确、完整。 3.第一季度报告是否经过审计 □是√否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | --- | --- | --- | --- | |-----------------------------------------------------|-----------------------------------|-------------------------------|------- ...

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the fiscal year 2021, representing a year-on-year growth of 25%[18]. - The net profit for the year was RMB 300 million, an increase of 30% compared to the previous year[18]. - The company's operating revenue for 2021 was ¥965,272,540.65, a decrease of 39.53% compared to ¥1,596,293,024.87 in 2020[25]. - The net profit attributable to shareholders for 2021 was ¥720,013,671.11, down 36.15% from ¥1,127,607,535.02 in 2020[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥596,583,791.15, a decline of 46.81% compared to ¥1,121,594,021.44 in 2020[25]. - The basic earnings per share for 2021 was ¥12.7061, a decrease of 42.53% from ¥22.1100 in 2020[25]. - The company reported a net cash flow from operating activities of ¥642,617,805.03, down 41.20% from ¥1,092,937,539.00 in 2020[25]. - The revenue from COVID-19 related business was ¥605,787,520.51, accounting for 62.76% of total revenue, down 54.86% from ¥1,342,074,558.04 in 2020[107]. - The revenue from non-COVID-19 related business was ¥359,485,020.14, showing a growth of 41.41% compared to the previous year[107]. Market Expansion and Strategy - The company is focusing on expanding its market presence in Southeast Asia, targeting a 20% market share by 2025[18]. - The company is exploring potential mergers and acquisitions to strengthen its market position, with a budget of RMB 1 billion for strategic investments[18]. - The company plans to enhance its marketing and service capabilities by expanding its customer service and logistics centers in key regions, including the Yangtze River Delta and Pearl River Delta[157]. - The company plans to focus on mergers and acquisitions to enhance its product line and technical capabilities, with some projects expected to reach cooperation or investment intentions in 2022[166]. Research and Development - The company has allocated RMB 200 million for research and development in 2022, aiming to enhance its technological capabilities[18]. - The company invested over 20 million yuan in advanced equipment, with overall R&D investment increasing by 53.99% year-on-year, enhancing its core competitiveness[91]. - The company’s R&D expenses for 2021 amounted to ¥40,129,306.95, representing a 53.99% increase compared to ¥26,059,125.31 in 2020[120]. - The company has developed a comprehensive quality management system, certified by ISO9001, ISO13485, and CNAS, ensuring product quality throughout its lifecycle[79]. - The company focuses on independent research and development, aiming to meet the demand for natural protein structures and properties in its recombinant protein offerings[68]. - The company has achieved rapid product development, exemplified by the ability to complete related protein development for COVID-19 in just six days, allowing for same-day or next-day delivery to domestic customers[47]. Product Development and Offerings - New product development includes the launch of a novel biopharmaceutical product expected to generate RMB 500 million in revenue in the first year[18]. - The company launched over 1,500 new biological reagent products in 2021, expanding its total product offerings to more than 52,000, including over 6,500 recombinant proteins and approximately 14,000 antibodies[68]. - The company has developed a product library of over 6,500 protein reagents and approximately 14,000 antibody reagents, with nearly 32,000 gene products available[94]. - The company is developing dry powder culture media to meet the increasing demand from industrial clients, as it offers lower unit costs and easier transportation compared to liquid media[158]. - The company is developing a high-affinity broad-spectrum influenza NP antibody kit, with one product already completed[124]. Customer Base and Market Demand - The company has a customer base that includes universities, research institutes, and pharmaceutical R&D enterprises, indicating a diverse market presence[69]. - The demand for customized products and services has been increasing, with the company’s customized R&D, production, and testing services showing sustained rapid growth[48]. - The company’s performance has been positively impacted by the growing need for one-stop procurement services, which require high R&D and production capabilities[46]. - The company generated 36.89% of its revenue from the U.S. market in 2021, highlighting its reliance on international markets[173]. Financial Management and Governance - The company has established a complete independent business and operational capability, with no reliance on the controlling shareholder in areas such as business operations, financial management, and human resources[182]. - The board of directors consists of 9 members, including 3 independent directors, and held 6 meetings in 2021 to ensure effective governance and decision-making[183]. - The company has a dedicated financial department with independent financial personnel and a standardized financial management system, ensuring financial independence from shareholders[194]. - The annual shareholders meeting on June 30, 2021, had a 100% investor participation rate[195]. - The meeting approved the financial budget report for 2021 and the profit distribution plan for 2020[195]. Risks and Challenges - The company has identified potential risks in supply chain disruptions and is implementing measures to mitigate these risks[6]. - The company recognizes the risk of revenue decline due to the potential decrease in demand for COVID-19 related products as the pandemic situation stabilizes[167]. - The company has faced operational risks due to the ongoing COVID-19 pandemic, which has affected the normal production and operation of some clients, leading to a slowdown in demand for products and services outside of COVID-19 related testing products[174]. - The company faces significant technical, talent, brand, and funding barriers, which create challenges for new entrants in the market[62].

Financial Performance - The company's revenue for Q3 2021 was ¥178,250,421.11, a decrease of 68.91% compared to the same period last year[4]. - Net profit attributable to shareholders for Q3 2021 was ¥113,712,536.77, down 72.66% year-on-year[4]. - The net profit after deducting non-recurring gains and losses was ¥98,477,492.32, reflecting a decline of 76.21% compared to the previous year[4]. - Basic and diluted earnings per share for Q3 2021 were both ¥2.0067, a decrease of 75.39% year-on-year[7]. - Total operating revenue for the current period is 812,948,531.27 CNY, a decrease of approximately 24% compared to 1,068,535,711.45 CNY in the previous period[48]. - Net profit for the current period is 556,362,582.99 CNY, down from 750,594,220.68 CNY, reflecting a decrease of around 26%[51]. - The total comprehensive income attributable to the parent company was CNY 557,545,024.32, compared to CNY 752,495,618.77 in the previous period, reflecting a decrease of approximately 26%[54]. - Basic and diluted earnings per share were CNY 10.5195, down from CNY 14.7175 in the previous period, indicating a decline of about 29.8%[54]. Assets and Liabilities - Total assets as of September 30, 2021, amounted to ¥6,679,292,731.77, an increase of 355.92% from the end of the previous year[7]. - The company's total assets amounted to RMB 6,679,292,731.77, a significant increase from RMB 1,465,027,156.89 as of December 31, 2020[38]. - Total liabilities decreased to 95,959,539.44 CNY from 166,383,639.22 CNY, a reduction of approximately 42%[44]. - Total liabilities reached 166,383,639.22, down from 189,672,693.69, indicating a reduction of 23,289,054.47[69]. - Owner's equity increased significantly to 6,583,333,192.33 CNY, compared to 1,298,643,517.67 CNY, representing an increase of about 408%[47]. - Owner's equity totaled 1,298,643,517.67, remaining unchanged from the previous period[72]. Cash Flow - The company reported a net cash flow from operating activities of ¥455,852,218.88, down 15.55% year-on-year[4]. - Cash inflow from operating activities totaled CNY 872,847,387.20, an increase from CNY 800,081,034.60 in the previous period, representing a growth of approximately 9%[57]. - Cash outflow from operating activities was CNY 416,995,168.32, compared to CNY 260,311,528.93 in the previous period, showing an increase of about 60%[57]. - Cash inflow from investment activities was CNY 2,545,611,806.61, significantly higher than CNY 292,363,345.33 in the previous period, indicating a substantial increase[60]. - Cash outflow from investment activities totaled CNY 3,123,661,450.28, compared to CNY 742,079,800.52 in the previous period, marking an increase of approximately 320%[60]. - Net cash flow from financing activities was CNY 4,720,050,530.28, a significant improvement from a net outflow of CNY 2,900,000.00 in the previous period[60]. - The cash and cash equivalents at the end of the period amounted to CNY 4,654,977,849.90, compared to CNY 96,907,321.22 in the previous period, showing a substantial increase[60]. - The company reported a net increase in cash and cash equivalents of CNY 4,598,862,076.90, compared to CNY 86,627,000.35 in the previous period, indicating a strong cash position[60]. Investments and Expenses - R&D expenses surged to ¥32,116,971.18, an increase of 84.01%, indicating a significant boost in research and development investments[15]. - Investment income rose dramatically by 1,885.69% to ¥27,071,806.61, attributed to returns from matured financial products[15]. - Financial expenses decreased by 80.93% to ¥2,593,271.97, primarily due to currency exchange rate fluctuations[15]. - The company received government subsidies amounting to ¥1,050,000.00 in the current period[9]. - Other income grew by 196.21% to ¥3,353,594.12, largely from received listing subsidies[15]. Future Plans and Strategies - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[4]. - The company plans to use RMB 114,500.00 million of the excess raised funds to permanently supplement its working capital, as approved in the board and shareholder meetings[29]. - The company intends to use RMB 90,384,095.37 to replace self-raised funds previously invested in projects, including RMB 82,838,085.94 for the biological reagent R&D center and RMB 7,546,009.43 for issuance costs[33]. - The company has approved the use of up to RMB 320,000.00 million of temporarily idle raised funds for cash management, investing in high-security and liquid financial products for a period of 12 months[34]. - The company has signed an agreement to establish a wholly-owned subsidiary in the Taizhou Medical High-tech Industrial Park, enhancing its operational footprint[37]. Audit and Compliance - The company has not audited the third-quarter report, which may affect stakeholder confidence in the reported figures[72]. - The company is expected to continue monitoring its financial position closely in light of the recent adjustments in asset and liability totals[72].

Financial Performance - The company's operating revenue for the first half of 2021 was ¥634,698,110.16, representing a 28.18% increase compared to ¥495,168,259.06 in the same period last year[26]. - The net profit attributable to shareholders for the first half of 2021 was ¥442,650,046.22, up 32.26% from ¥334,673,923.85 in the previous year[26]. - The basic earnings per share for the first half of 2021 were ¥8.6794, which is a 32.26% increase from ¥6.5622 in the same period last year[26]. - Operating profit for the first half of 2021 was ¥528,749,034.32, an increase of 35.3% compared to ¥391,163,462.78 in the same period of 2020[179]. - The company's total comprehensive income for the first half of 2021 was ¥443,731,854.77, compared to ¥335,906,628.85 in the same period of 2020[182]. Cash Flow and Assets - The net cash flow from operating activities increased significantly by 169.78%, reaching ¥390,173,692.51 compared to ¥144,628,395.61 in the same period last year[26]. - Cash and cash equivalents as of June 30, 2021, amounted to ¥145,312,733.18, an increase from ¥56,115,773.00 at the end of 2020[157]. - The company reported a net cash flow from operating activities of ¥387,039,912.91, compared to ¥99,730,971.72 in the previous year[199]. - Total cash inflow from operating activities was ¥710,198,902.01, compared to ¥286,525,831.83 in the previous year[195]. - The company experienced a net increase in cash and cash equivalents of ¥89,196,960.18, compared to ¥58,762,882.93 in the previous year[198]. Assets and Liabilities - The total assets of the company at the end of the reporting period were ¥1,854,707,489.68, a 26.60% increase from ¥1,465,027,156.89 at the end of the previous year[26]. - The company's equity attributable to shareholders rose to ¥1,744,581,040.08, up from ¥1,298,643,517.67, marking an increase of around 34.3%[166]. - Total liabilities decreased to ¥110,126,449.60 from ¥166,383,639.22, indicating a reduction of approximately 33.7%[163]. - Accounts receivable decreased to ¥141,804,830.74, accounting for 7.65% of total assets, down from 13.26% the previous year, primarily due to improved collection[55]. - The trading financial assets increased to ¥1,380,175,561.87 from ¥1,072,708,285.69 year-over-year[157]. Revenue Breakdown - Revenue from non-epidemic virus-related business reached 177 million yuan, up 45.05% year-on-year[40]. - Revenue from epidemic virus-related business was 458 million yuan, an increase of 22.67% compared to the previous year[40]. - Revenue from the U.S. market accounted for 64.49% of total revenue during the reporting period, highlighting the importance of this market for the company[78]. - The company's revenue for the reporting period reached ¥634,698,110.16, representing a year-on-year increase of 28.18% due to growth in both pandemic-related and non-pandemic product sales[52]. Research and Development - R&D investment increased by 70.43% to ¥18,280,828.79, reflecting ongoing commitment to developing protein and antibody products[52]. - The company has developed a product library with over 6,000 protein reagents and approximately 13,000 antibody reagents, indicating strong R&D capabilities[46]. - The company has developed a series of core technology platforms to meet the diverse needs of biological research units[38]. - The company provides customized technical services for recombinant protein expression and purification, antibody development, and production[39]. Market and Competition - The company faces several risks, including performance decline, new product development risks, and intensified industry competition[6]. - The company has established stable partnerships with renowned research institutions and pharmaceutical companies, enhancing its brand and market reputation[50]. - The company has established a global market presence, with products sold in over 90 countries, enhancing its market competitiveness[48]. - The global biopharmaceutical research and life sciences market is expected to see continued investment growth due to increasing health concerns and government support[41]. Strategic Initiatives - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[6]. - The company intends to invest in mergers and acquisitions of high-quality domestic and international enterprises to enhance its product line and technical capabilities[86]. - The company plans to continue independent research and development, aiming to enrich its existing product lines and enhance its technological capabilities[80]. - The company aims to develop high-quality diagnostic reagent raw materials based on its existing research capabilities in recombinant proteins and antibodies[84]. Compliance and Governance - The company has complied with environmental regulations and has not faced any significant administrative penalties during the reporting period[97]. - The company has not engaged in any significant litigation or arbitration matters during the reporting period[114]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[108]. - The half-year financial report has not been audited[110].